# CME ACTIVITY SERIES HIGHLIGHTS CHANGES IN CLINICIANS' KNOWLEDGE AND COMPETENCE ABOUT NOVEL APPROACHES TO REDUCE DKD PROGRESSION

Shpetim Karandrea, PhD; Neha Agarwal, PhD*; Amanda Jamrogiewicz, CHCP; Cardiometabolic Health Congress, Boca Raton, FL

Presented at the 2022 American Diabetes Association Scientific Sessions

## BACKGROUND

We sought to determine the impact of a series of CME activities on the knowledge and competence of multi-disciplinary clinicians about novel approaches to reduce diabetic kidney disease (DKD) progression, with a focus on non-steroidal mineralocorticoid antagonists (MRAs).

## METHODS

**PRE-ACTIVITY SURVEY**
Knowledge & Competence

**LIVE VIRTUAL PRIMETIME SYMPOSIUM AT 2020 CMHC ANNUAL: 10/2020**

**LIVE ONLINE SYMPOSIUM AT RENAL PHYSICIANS ANNUAL MEETING: 3/2021**

**VIRTUAL SATELLITE SYMPOSIUM (WCN/ISN): 4/2021**

**LIVE PRIMETIME SYMPOSIUM AT 2021 CMHC ANNUAL: 10/2021**

**POST-ACTIVITY SURVEY**
Knowledge, Competence, Barriers to Best Practice, Intended Changes

## RESULTS

### LEARNER DEMOGRAPHICS

**829** Learners **347** Certificates

#### DEGREE BREAKDOWN


#### SPECIALTY BREAKDOWN




## IMPACT ON KNOWLEDGE & COMPETENCE

### Knowledge Across Key Areas




### Competence




## INTENDED PRACTICE CHANGES




## ONGOING EDUCATIONAL GAPS

- Residual DKD risk and which pathophysiological processes do non-steroidal MRAs target
- Diagnosis and assessment of DKD
- Steroidal vs. nonsteroidal MRAs (mechanism of action, efficacy, safety, rationale for non-steroidal MRA)
- Results of ongoing clinical trials with nonsteroidal MRAs and additional sub-analyses of major trials
- Since finerenone received a recent FDA approval, its potential role in the treatment of DKD needs to be discussed further

## CONCLUSIONS

- The study demonstrated significant improvement in knowledge and competence related to novel DKD treatment options and commitment to change among learners.
- Although important educational gains were achieved, since this is a relatively novel approach, additional education is needed to better understand the role of finerenone. These may include perspectives on how it fits in with existing treatment options and more notably with SGLT-2 inhibitors, patient selection, as well as ongoing trials and additional future applications, including for the treatment of chronic kidney disease (CKD) without type 2 diabetes.

## ACKNOWLEDGEMENTS & RESOURCES

This activity was jointly provided by the Cardiometabolic Health Congress and Postgraduate Institute for Medicine

Supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc.

SCAN ME
for a PDF version

SCAN ME
for more information and resources on DKD

DISCLOSURES
The authors report no conflicts of interest as it relates to this presentation